This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
GENE THERAPY may still be in its infancy, but it is cutting teeth on attempts to ameliorate human immunodeficiency virus (HIV) disease.
Indeed, knowledge about the HIV genome seems to have come faster than clinical advances in treating the infection itself, and work with HIV clearly is breaking new ground in the field of gene therapy in ways likely to have impact far beyond the treatment of AIDS.
The National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md, is including several gene therapy approaches, along with other innovative cell transfer studies, in the new Strategic Program for Innovative Research on AIDS Treatment (SPIRAT). SPIRAT is "crucial," says NIAID Director Anthony Fauci, MD, because anti-HIV drugs "only partially and temporarily suppress" viral replication and are "hampered by toxicity and drug resistance."
Enthusiasm and Cooperation
There is "great enthusiasm about the potential of gene therapy" for treating HIV disease, says William
Cotton P. High-tech Assault on HIV: Gene Therapy. JAMA. 1994;272(16):1235–1236. doi:10.1001/jama.1994.03520160017007
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: